Developer docs
API playgroundTry for free, no card

Search company profiles

Ascendia Pharmaceutical Solutions

Full company profile

uuid0000y8r

Namestring
Ascendia Pharmaceutical Solutions
Legal namestring
Ascendia Pharmaceutical Solutions
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Ascendia Pharmaceutical Solutions is a U.S.-based specialty Contract Development and Manufacturing Organization (CDMO) headquartered in North Brunswick, New Jersey, founded in 2012–2013. The company provides complex formulation development and cGMP manufacturing services to pharmaceutical and biotech clients across the full drug-development lifecycle, from pre-formulation screening through commercialization. Ascendia operates a single facility in North Brunswick where 100% of its formulation development and manufacturing is conducted under GMP/cGMP standards.

The company's technical foundation rests on four proprietary nano-technology platforms built from GRAS materials — LipidSol® (lipid nanoparticles for encapsulating small and large molecules), EmulSol® (oil-in-water nano-emulsions), AmorSol® (amorphic solid dispersions), and NanoSol® (nano-sized drug particles) — complemented by a Controlled Release technology platform. These platforms address solubility, permeability, and bioavailability challenges for small molecules, biologics, and gene delivery applications. Service offerings include pre-formulation screening, formulation development, analytical services, small-scale formulations, ICH stability studies, sterile parenteral manufacturing, oral/liquid/solid dosage manufacturing, and clinical trial materials production.

Ascendia generates revenue through professional-services-style contracts (quote-based, project-specific engagements) sold via a direct B2B enterprise sales motion targeting pharmaceutical and biotech decision-makers. The company self-reports having doubled revenue over the past two years and being named one of the fastest-growing private U.S. companies for four consecutive years. Recent capital activity includes three ~$2.5M securities offerings in 2022, 2024, and 2025, with early institutional participation from Signet Healthcare Partners in 2021. Leadership comprises Jim J Huang (CEO and Founder) and Robert Bloder (Chief Business Officer).

Short descriptiontext

Ascendia Pharmaceutical Solutions is a U.S.-based specialty CDMO providing complex formulation development and cGMP manufacturing services to pharmaceutical and biotech companies, leveraging four proprietary nano-technology platforms to address solubility and bioavailability challenges across the drug development lifecycle.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNorth Brunswick, United States
HQ citystring
North Brunswick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, formulation development, cGMP manufacturing, nano drug delivery, clinical trial materials
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

CDMO services including formulation development, analytical services, GMP/cGMP manufacturing, and clinical trial materials production for pharmaceutical and biotech companies on a contract basis.

ascendiacdmo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ascendia is a specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers nano-technology-based drug formulation and cGMP manufacturing services. It operates four proprietary platforms (LipidSol®, EmulSol®, AmorSol®, NanoSol®) plus Controlled Release technology, and provides pre-formulation, formulation development, analytical services, ICH stability studies, and cGMP clinical trial material manufacturing for pharma and biotech clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 4 proprietary technologies from all GRAS materials
+1 more record
Product overview1 text field

Ascendia Pharmaceutical Solutions operates as a specialty pharma CDMO (Contract Development and Manufacturing Organization) providing a unified platform of proprietary nanotechnologies integrated with comprehensive drug development services. The core offering centers on four patented technology platforms: LipidSol® (lipid nanoparticles), EmulSol® (nano-emulsions), AmorSol® (amorphic solid dispersions), and NanoSol® (nano-sized drug particles), all built from GRAS materials. These technologies are complemented by a full suite of services spanning pre-formulation, formulation development, analytical services, GMP/cGMP manufacturing, clinical trial materials production, and ICH stability studies. The portfolio enables pharmaceutical and biotech companies to overcome drug development challenges—particularly solubility barriers—from pre-formulation through commercialization, serving both small molecules and biologics/gene delivery applications.

Product and service1 record
1LipidSol®
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

U.S.-based mid-tier CDMO offering formulation development, analytical services, and cGMP clinical/commercial manufacturing for small molecules. Highly comparable mid-sized CDMO peer to Ascendia.

TypeDirect peer
Description

Specialty CDMO focused on early-phase small-molecule development including formulation, analytical, and cGMP clinical manufacturing. Closely comparable in scope to Ascendia's early-clinical-stage offering.

TypeDirect peer
Description

Specialty CDMO with strong capabilities in solubility-enhancement technologies, particle engineering, and amorphous solid dispersions. Closely comparable to Ascendia's AmorSol and NanoSol platforms and small-molecule CDMO focus.

TypeDirect peer
Description

One of the largest global specialty CDMOs offering formulation development, sterile fill-finish, and clinical/commercial manufacturing across oral, injectable, and biologic dosage forms. Direct competitor to Ascendia's specialty CDMO service offering.

TypeBroad incumbent
Description

One of the world's largest CDMOs offering integrated small-molecule and biologics development and manufacturing. Represents the scaled incumbent Ascendia competes against for larger pharma programs.

TypeDirect peer
Description

Mid-sized European CDMO offering solid, semi-solid, and sterile dosage form development and manufacturing. Comparable mid-tier specialty CDMO with similar scope across oral and parenteral formats.

TypeBroad incumbent
Description

Global CDMO services through its Patheon business covering formulation, clinical and commercial manufacturing, and integrated drug substance/product offerings. Direct large-incumbent competitor across Ascendia's service lines.

TypeDirect peer
Description

Specialty CDMO focused on complex oral dosage forms, taste-masking, and modified-release technologies. Direct comparable in the complex-formulation niche Ascendia serves.

TypeBroad incumbent
Description

Large global CDMO with extensive formulation, manufacturing, and analytical capabilities. Major pricing competitor for formulation and clinical-supply work and representative of the offshore CDMO capacity that U.S. sponsors may reduce reliance on.

TypeRegional player
Description

Vertically integrated pharmaceutical manufacturer with growing CDMO services in injectable and oral solid dose manufacturing. Adjacent comparability on sterile parenteral and oral solid dose capabilities though primarily India-based.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ascendia Pharmaceutical Solutions

Pharmaceutical Contract Development and Manufacturing (CDMO)ascendiacdmo.com

Ascendia Pharmaceutical Solutions is a U.S.-based specialty CDMO providing complex formulation development and cGMP manufacturing services to pharmaceutical and biotech companies, leveraging four proprietary nano-technology platforms to address solubility and bioavailability challenges across the drug development lifecycle.

What Ascendia Pharmaceutical Solutions does

Ascendia Pharmaceutical Solutions is a U.S.-based specialty Contract Development and Manufacturing Organization (CDMO) headquartered in North Brunswick, New Jersey, founded in 2012–2013. The company provides complex formulation development and cGMP manufacturing services to pharmaceutical and biotech clients across the full drug-development lifecycle, from pre-formulation screening through commercialization. Ascendia operates a single facility in North Brunswick where 100% of its formulation development and manufacturing is conducted under GMP/cGMP standards.

The company's technical foundation rests on four proprietary nano-technology platforms built from GRAS materials — LipidSol® (lipid nanoparticles for encapsulating small and large molecules), EmulSol® (oil-in-water nano-emulsions), AmorSol® (amorphic solid dispersions), and NanoSol® (nano-sized drug particles) — complemented by a Controlled Release technology platform. These platforms address solubility, permeability, and bioavailability challenges for small molecules, biologics, and gene delivery applications. Service offerings include pre-formulation screening, formulation development, analytical services, small-scale formulations, ICH stability studies, sterile parenteral manufacturing, oral/liquid/solid dosage manufacturing, and clinical trial materials production.

Ascendia generates revenue through professional-services-style contracts (quote-based, project-specific engagements) sold via a direct B2B enterprise sales motion targeting pharmaceutical and biotech decision-makers. The company self-reports having doubled revenue over the past two years and being named one of the fastest-growing private U.S. companies for four consecutive years. Recent capital activity includes three ~$2.5M securities offerings in 2022, 2024, and 2025, with early institutional participation from Signet Healthcare Partners in 2021. Leadership comprises Jim J Huang (CEO and Founder) and Robert Bloder (Chief Business Officer).

Ascendia Pharmaceutical Solutions firmographics

Firmographics
Name
Ascendia Pharmaceutical Solutions
Legal name
Ascendia Pharmaceutical Solutions
Website
https://ascendiacdmo.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Ascendia Pharmaceutical Solutions is a U.S.-based specialty CDMO providing complex formulation development and cGMP manufacturing services to pharmaceutical and biotech companies, leveraging four proprietary nano-technology platforms to address solubility and bioavailability challenges across the drug development lifecycle.
Ownership category
akta.pro rank

Ascendia Pharmaceutical Solutions industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Formulation development
  • CGMP manufacturing
  • Nano drug delivery
  • Clinical trial materials

Where Ascendia Pharmaceutical Solutions is headquartered

Location

Headquarters

HQ city
North Brunswick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ascendia Pharmaceutical Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: CDMO services including formulation development, analytical services, GMP/cGMP manufacturing, and clinical trial materials production for pharmaceutical and biotech companies on a contract basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ascendia Pharmaceutical Solutions product offering

Product offering

Core offering

Ascendia is a specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers nano-technology-based drug formulation and cGMP manufacturing services. It operates four proprietary platforms (LipidSol®, EmulSol®, AmorSol®, NanoSol®) plus Controlled Release technology, and provides pre-formulation, formulation development, analytical services, ICH stability studies, and cGMP clinical trial material manufacturing for pharma and biotech clients.

Product overview

Ascendia Pharmaceutical Solutions operates as a specialty pharma CDMO (Contract Development and Manufacturing Organization) providing a unified platform of proprietary nanotechnologies integrated with comprehensive drug development services. The core offering centers on four patented technology platforms: LipidSol® (lipid nanoparticles), EmulSol® (nano-emulsions), AmorSol® (amorphic solid dispersions), and NanoSol® (nano-sized drug particles), all built from GRAS materials. These technologies are complemented by a full suite of services spanning pre-formulation, formulation development, analytical services, GMP/cGMP manufacturing, clinical trial materials production, and ICH stability studies. The portfolio enables pharmaceutical and biotech companies to overcome drug development challenges—particularly solubility barriers—from pre-formulation through commercialization, serving both small molecules and biologics/gene delivery applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • LipidSol®

Quantifiable outcome

  • 4 proprietary technologies from all GRAS materials
  • +1 more outcomes

Companies that use Ascendia Pharmaceutical Solutions

Customer profile

Segments2 records

Ideal customer profiles2 records

Ascendia Pharmaceutical Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ascendia Pharmaceutical Solutions partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Ascendia Pharmaceutical Solutions competitors and assessment

Company assessment

Direct peers

  • Alcami: U.S.-based mid-tier CDMO offering formulation development, analytical services, and cGMP clinical/commercial manufacturing for small molecules. Highly comparable mid-sized CDMO peer to Ascendia.
  • Ardena: Specialty CDMO focused on early-phase small-molecule development including formulation, analytical, and cGMP clinical manufacturing. Closely comparable in scope to Ascendia's early-clinical-stage offering.
  • Hovione: Specialty CDMO with strong capabilities in solubility-enhancement technologies, particle engineering, and amorphous solid dispersions. Closely comparable to Ascendia's AmorSol and NanoSol platforms and small-molecule CDMO focus.
  • Catalent: One of the largest global specialty CDMOs offering formulation development, sterile fill-finish, and clinical/commercial manufacturing across oral, injectable, and biologic dosage forms. Direct competitor to Ascendia's specialty CDMO service offering.
  • Aenova Group: Mid-sized European CDMO offering solid, semi-solid, and sterile dosage form development and manufacturing. Comparable mid-tier specialty CDMO with similar scope across oral and parenteral formats.
  • Adare Pharma Solutions: Specialty CDMO focused on complex oral dosage forms, taste-masking, and modified-release technologies. Direct comparable in the complex-formulation niche Ascendia serves.

Broad incumbents

  • Lonza: One of the world's largest CDMOs offering integrated small-molecule and biologics development and manufacturing. Represents the scaled incumbent Ascendia competes against for larger pharma programs.
  • Thermo Fisher Scientific (Patheon): Global CDMO services through its Patheon business covering formulation, clinical and commercial manufacturing, and integrated drug substance/product offerings. Direct large-incumbent competitor across Ascendia's service lines.
  • WuXi STA (WuXi AppTec): Large global CDMO with extensive formulation, manufacturing, and analytical capabilities. Major pricing competitor for formulation and clinical-supply work and representative of the offshore CDMO capacity that U.S. sponsors may reduce reliance on.

Regional players

  • Aurobindo Pharma / Auro Vaccines CDMO arm: Vertically integrated pharmaceutical manufacturer with growing CDMO services in injectable and oral solid dose manufacturing. Adjacent comparability on sterile parenteral and oral solid dose capabilities though primarily India-based.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ascendia Pharmaceutical Solutions social profiles

Digital presence

Ascendia Pharmaceutical Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ascendia Pharmaceutical Solutions leadership team

Management profile

Number of profiles

Profiles2 records

Ascendia Pharmaceutical Solutions funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ascendia Pharmaceutical Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascendia Pharmaceutical Solutions

What does Ascendia Pharmaceutical Solutions do?

Ascendia is a specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers nano-technology-based drug formulation and cGMP manufacturing services. It operates four proprietary platforms (LipidSol®, EmulSol®, AmorSol®, NanoSol®) plus Controlled Release technology, and provides pre-formulation, formulation development, analytical services, ICH stability studies, and cGMP clinical trial material manufacturing for pharma and biotech clients.

Is Ascendia Pharmaceutical Solutions a public or private company?

Ascendia Pharmaceutical Solutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ascendia Pharmaceutical Solutions founded?

Ascendia Pharmaceutical Solutions was founded in 2013. It employs 51 to 100 people.

Where is Ascendia Pharmaceutical Solutions based?

Ascendia Pharmaceutical Solutions is headquartered in North Brunswick, United States, in the North America region.

How does Ascendia Pharmaceutical Solutions make money?

One revenue line is on record: contract Development and Manufacturing Services.

Who are Ascendia Pharmaceutical Solutions's main competitors?

Direct peers on record are Alcami, Ardena, Hovione, Catalent, Aenova Group and Adare Pharma Solutions. Broad incumbents are Lonza, Thermo Fisher Scientific (Patheon) and WuXi STA (WuXi AppTec). Aurobindo Pharma / Auro Vaccines CDMO arm is listed as a regional player.

Does Ascendia Pharmaceutical Solutions have an API?

No public API is recorded for Ascendia Pharmaceutical Solutions.

What industry is Ascendia Pharmaceutical Solutions in?

Ascendia Pharmaceutical Solutions's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals